The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase I, open-label, dose escalation, confirmation, and expansion trial of BI 1810631 as monotherapy in patients with advanced/metastatic solid tumors with HER2 aberrations.
 
John Heymach
Stock and Other Ownership Interests - Bio-Tree; Cardinal Spine
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; BrightPath Biotheraputics; Bristol-Myers Squibb; Catalyst Biotech; EMD Serono; Foundation medicine; Genentech/Roche; GlaxoSmithKline; Guardant Health; Hengrui Pharmaceutical; Janssen; Kairos Ventures; Leads Biolabs; Lilly; Mirati Therapeutics; Nexus Health Systems; Novartis; Pneuma Respiratory; Roche; Sanofi/Aventis; Spectrum Pharmaceuticals; Takeda
Research Funding - AstraZeneca (Inst); GlaxoSmithKline; Spectrum Pharmaceuticals
Patents, Royalties, Other Intellectual Property - Licensing agreement between Spectrum and MD Anderson (including myself) regarding intellectual property for treatment of EGFR and HER2 exon 20 mutations
 
Frans Opdam
(OPTIONAL) Uncompensated Relationships - AstraZeneca/Merck (Inst); Boehringer Ingelheim (Inst); Cytovation (Inst); GlaxoSmithKline (Inst); InteRNA (Inst); Merus NV (Inst); Pierre Fabre (Inst); Taiho Oncology (Inst)
 
Minal A. Barve
Employment - Texas Oncology
Stock and Other Ownership Interests - Texas Oncology
Research Funding - Mary Crowley Research Center, Dallas Texas
 
Neil Gibson
Employment - Boehringer Ingelheim
 
Behbood Sadrolhefazi
Employment - Boehringer Ingelheim
 
Josep Serra
Employment - Boehringer Ingelheim
 
Noboru Yamamoto
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo/UCB Japan; Eisai; Lilly Japan; Ono Pharmaceutical; Pfizer; Sysmex
Consulting or Advisory Role - Boehringer Ingelheim; Chugai Pharma; CMIC; Eisai; Otsuka; Takeda
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Carna Biosciences (Inst); Chiome Bioscience (I); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Genmab/Seattle Genetics (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Otsuka (I); Pfizer (Inst); Shionogi (Inst); Sumitomo Dainippon (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)